IP Library Granted Patent US 6,867,025
Granted Patent B2
US 6,867,025 · App. 10/154,674 · Granted Mar 15, 2005

Human hydroxylases and polynucleotides encoding the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,867,025
App. No.
10/154,674
Granted
Mar 15, 2005
Kind
B2
Abstract

Novel human polynucleotide and polypeptide sequences are disclosed that can be used in industrial, therapeutic, diagnostic, and pharmacogenomic applications.

Claims (16)

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:7.

2. The isolated nucleic acid molecule of claim 1 , wherein the molecule comprises the nucleotide sequence of SEQ ID NO:5.

3. The isolated nucleic acid molecule of claim 2 , wherein the molecule comprises the nucleotide sequence of SEQ ID NO:3.

4. The isolated nucleic acid molecule of claim 3 , wherein the molecule comprises the nucleotide sequence of SEQ ID NO:1.

5. An isolated nucleic acid molecule comprising a nucleotide sequence that:

(a) encodes the amino acid sequence shown in SEQ ID NO:4; and

(b) hybridizes under highly stringent conditions to the nucleotide sequence of SEQ ID NO:3 or the complement thereof.

6. An isolated nucleic acid molecule encoding the amino acid sequence described in SEQ ID NO:8.

7. The isolated nucleic acid molecule of claim 6 , wherein the molecule encodes the amino acid sequence of SEQ ID NO:6.

8. The isolated nucleic acid molecule of claim 7 , wherein the molecule encodes the amino acid sequence of SEQ ID NO:4.

9. The isolated nucleic acid molecule of claim 8 , wherein the molecule encodes the amino acid sequence of SEQ ID NO:2.

10. A substantially isolated protein having the activity of the protein shown in SEQ ID NOS:2, 4, 6, or 8, which is encoded by a nucleotide sequence that hybridizes to SEQ ID NO:1, 3, 5, or 7 under highly stringent conditions.

11. The substantially isolated protein of claim 10 , wherein said protein comprises he amino acid sequence of SEQ ID NO:8.

12. The substantially isolated protein of claim 10 , wherein said protein comprises he amino acid sequence of SEQ ID NO:6.

13. The substantially isolated protein of claim 10 , wherein said protein comprises he amino acid sequence of SEQ ID NO:4.

14. The substantially isolated protein of claim 10 , wherein said protein comprises he amino acid sequence of SEQ ID NO:2.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded May 5, 2026
From: OXFORD FINANCE LLC
To: LEXICON PHARMACEUTICALS, INC.; LEXICON PHARMACEUTICALS
Reel/Frame 075545/0601 →
SECURITY INTEREST Recorded Mar 17, 2022
From: LEXICON PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 059432/0709 →
CHANGE OF NAME Recorded Feb 24, 2022
From: LEXICON GENETICS INCORPORATED
To: LEXICON PHARMACEUTICALS, INC.
Reel/Frame 059240/0463 →
RELEASE OF SECURITY INTEREST Recorded Sep 14, 2020
From: BIOPHARMA CREDIT PLC
To: LEXICON PHARMACEUTICALS, INC.
Reel/Frame 053767/0445 →
SECURITY INTEREST Recorded Dec 20, 2017
From: LEXICON PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 044958/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2002
From: YU, XUANCHUAN; MIRANDA, MARICAR; HU, YI
To: LEXICON GENETICS INCORPORATED
Reel/Frame 013246/0138 →